JHS Svendgaard Board Approves Q2 FY26 Un-Audited Financial Results; Reports Quarterly Loss, Half-Yearly Profit
JHS Svendgaard's Board approved Q2 FY26 financial results. The company reported a net loss for the quarter but a significant profit turnaround for the half-year, with ongoing strategic fund utilization.
The announcement of quarterly and half-yearly financial results, including revenue, profit/loss, and EPS, is a high-impact event as it directly reflects the company's financial health and operational performance to investors.
The sentiment is neutral due to mixed financial performance; while the company reported a net loss for the quarter ended September 30, 2025, it showed a significant turnaround to profit for the half-year compared to the previous year's half-year loss. Fund utilization for projects is a positive.
* The Board of Directors of JHS Svendgaard Laboratories Limited, at their meeting on November 14, 2025, approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2025. * For the quarter ended September 30, 2025 (Q2 FY26): * Standalone Revenue from operations stood at ₹2,227.71 lakhs, with a Net Loss of ₹19.67 lakhs. Basic Earnings Per Share (EPS) was ₹(0.02). * Consolidated Revenue from operations was ₹2,227.71 lakhs, with a Net Loss of ₹19.77 lakhs. Basic EPS was ₹(0.02). * In comparison, for the quarter ended September 30, 2024 (Q2 FY25), the company reported a Standalone Net Profit of ₹105.57 lakhs (EPS ₹0.12) and a Consolidated Net Profit of ₹105.52 lakhs (EPS ₹0.11). * For the half-year ended September 30, 2025 (H1 FY26): * Standalone Net Profit was ₹85.90 lakhs, a significant improvement from a Net Loss of ₹1,094.61 lakhs in H1 FY25. * Consolidated Net Profit was ₹85.74 lakhs, also a significant improvement from a Net Loss of ₹1,094.89 lakhs in H1 FY25. * Funds from the preferential allotment in August 2024 (₹20 crore from equity shares and ₹2.5 crore from warrants) have been utilized as follows: * ₹71.29 lakhs for a project in Jammu and Kashmir. * ₹749.50 lakhs for General Corporate Purpose. * ₹229.62 lakhs for Capital Expenditure. * A balance of ₹1,200.60 lakhs has been parked in fixed deposits, pending utilization. * M/s V.K. Khosla & Co., Chartered Accountants, issued Limited Review Reports on both standalone and consolidated financial results.
What to do with a filing like this
JHS Svendgaard Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by JHS Svendgaard Laboratories Limited. Read the original for the full detail.